AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03370055 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LeucoPatch®
Description: LeucoPatch® is an elastic membrane produced by the patients own venous blood by centrifugation, and one or two is placed on the wound once a week The LeucoPatch® consist of the fibrin Leucocytes and growth factors from the patients own blood
Study NCT03370055 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control,
Description: Usual wound care in a specialized clinic
Study NCT03370055 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control,
Description: Usual wound care in a specialized clinic
Study NCT00975806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide MTD mg by mouth (PO) daily for Days 1- 21 in combination
Study NCT00975806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib 37.5 mg PO daily on days 1-21 of each 21-day cycle in Cohort A or on days 1-14 in Cohorts F and G
Study NCT03775447 — intervention group
Intervention type: PROCEDURE
Intervention: Lumbar Puncture
Description: Lumbar Puncture for collection of Cerebrospinal Fluids
Study NCT04599582 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hip Arthroplasty
Description: Patients are operated with hip replacement.
Study NCT00807846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib 50 mg or 100 mg PO BID for 6 weeks
Study NCT00807846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: Naproxen 7.5 mg/kg PO BID \[maximum of 500 mg BID\] for 6 weeks
Study NCT03340181 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RIPC
Description: 4 cycles of 5-min ischemia(using a blood pressure cuff inflated to 40mmHg over the patient's basic blood pressure) and 5-min repercussion are done on an upper limb before skin incision.
Study NCT03340181 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: RIPC
Description: 4 cycles of 5-min ischemia(using a blood pressure cuff inflated to 40mmHg over the patient's basic blood pressure) and 5-min repercussion are done on an upper limb before skin incision.
Study NCT02621268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: Infusion of ICG 24 hours prior to surgery
Study NCT03890887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1291583
Description: Tablet
Study NCT03890887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Oral solution
Study NCT01290081 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Case management approach in referral to health care services
Description: Case management intervention aimed at increasing TB screening and treatment entry among injecting drug users referred from a methadone drug treatment program
Study NCT01290081 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Case management approach in referral to health care services
Description: Case management intervention aimed at increasing TB screening and treatment entry among injecting drug users referred from a methadone drug treatment program
Study NCT00102453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Pentoxifylline dosing: 20mg/Kg/day in a 20 mg/mL solution. Maximum dose of 1200mg/day. Dosing split into two equal parts taken morning and night with food.
Study NCT02391506 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cartiva
Description: Cartiva Synthetic Cartilage Implant
Study NCT00303108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin
Description: 30 mg/m2 IV on Day 1 of each 28 day cycle
Study NCT00303108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC=5 on Day 1 of each 28 day cycle
Study NCT00303108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: 4 mg/kg on Days 1 and 15 of each cycle(loading dose of 8 mg/kg on Day 1 of Cycle 1 only)
Study NCT00756587 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cup Feeding
Description: using a cup feeding technique for feeding the preterm infants during NICU stay
Study NCT00756587 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bottle Feeding
Description: receiving all feeding by bottle
Study NCT03492463 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch
Description: Participants will wear the nicotine patch daily while switching from cigarette use to use of e-cigarettes for eight weeks.
Study NCT03492463 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo patch
Description: Participants will wear the placebo patch daily while switching from cigarette use to use of e-cigarettes for eight weeks.
Study NCT03511885 — intervention group
Intervention type: OTHER
Intervention: There is no intervention
Study NCT00513617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arginine
Description: Depending on the weight of the child or adult, the patients took any where between 4-10 capsules 2 times a day. Patients weighing less than 45 kilograms were on the low dose active (or placebo) so the capsules were smaller. Patients greater than or equal to 45 kgs were on the high dose active or placebo, so these capsules were larger.
Study NCT00513617 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Depending on the weight of the child or adult, the patients took any where between 4-10 capsules 2 times a day. Patients weighing less than 45 kilograms were on the low dose active (or placebo) so the capsules were smaller. Patients greater than or equal to 45 kgs were on the high dose active or placebo, so these capsules were larger.
Study NCT01151319 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdV63.HIVconsv low dose.
Description: Attenuated chimp adenovirus. 5x10\^9 virus particles.
Study NCT01151319 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdV63.HIVconsv high dose.
Description: Attenuated chimp adenovirus at 5x10\^10 virus particles.
Study NCT01151319 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pSG2.HIVconsv
Description: DNA at 4mg per dose.
Study NCT03577457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal placebo treatment (placebo-control for oxytocin)
Description: intranasal administration of placebo nasal spray
Study NCT01151319 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA.HIVconsv
Description: Attenuated poxvirus at 4x10\^8 plaque forming units per dose.
Study NCT01151319 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phosphate buffered saline
Study NCT03808584 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: 4 specific core muscle exercises, targeting abdominal muscles, to be performed daily from postoperative day one to 2 months postsurgery.
Study NCT03577457 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intranasal placebo treatment (placebo-control for oxytocin)
Description: intranasal administration of placebo nasal spray
Study NCT03577457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral placebo treatment (placebo-control for ATD)
Description: oral administration of a tryptophan-balanced mixture (78.2g)
Study NCT03577457 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oral placebo treatment (placebo-control for ATD)
Description: oral administration of a tryptophan-balanced mixture (78.2g)
Study NCT03346837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986205
Description: BMS-986205
Study NCT03492463 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo patch
Description: Participants will wear the placebo patch daily while switching from cigarette use to use of e-cigarettes for eight weeks.
Study NCT03492463 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: E-cigarettes
Description: Participants will use e-cigarettes containing nicotine while switching from cigarette use to use of e-cigarettes for eight weeks.
Study NCT03346837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Oral solution
Study NCT03346837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Tablet
Study NCT02279056 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-help book for insomnia
Description: RCT comparing efficacy of a self-help book for insomnia and sleep hygiene advice in patients with co-morbid OSA and insomnia.
Study NCT02279056 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sleep hygiene advice
Description: RCT comparing efficacy of a self-help book for insomnia and sleep hygiene advice in patients with co-morbid OSA and insomnia.
Study NCT03747367 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Insufficient Sleep
Study NCT03416894 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: DBS offers the opportunity to insert electrodes into deep brain structures and electrically stimulate them in a titratable and ultimately reversible manner
Study NCT01019941 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: CKD-810, Taxotere inj.
Description: Patients will receive docetaxel 75mg/㎡ on Day 1 of each cycle(1 cycle = 3 weeks) as a 1-hour IV infusion. At the 1st cycle, CKD-810 75mg/㎡ administered. If the hematologic or non-hematologic toxicity was not appeared when the 1st cycle intervention was finished, keep going the 2nd cycle intervention.
Study NCT01019941 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: CKD-810, Taxotere inj.
Description: Patients will receive docetaxel 75mg/㎡ on Day 1 of each cycle(1 cycle = 3 weeks) as a 1-hour IV infusion. At the 1st cycle, Taxotere inj. 75mg/㎡ administered. If the hematologic or non-hematologic toxicity was not appeared when the 1st cycle intervention was finished, keep going the 2nd cycle intervention.
Study NCT03622151 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Primer la Llar program
Description: Housing First model: permanent housing without previous requirements such as abstinence, sobriety or compliance with treatment.
Study NCT04838067 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cefaly
Description: Transcutaneous trigeminal nerve electrical neuromodulation
Study NCT03492463 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-nicotine e-cigarettes
Description: Participants will use e-cigarettes not containing nicotine while switching from cigarette use to use of e-cigarettes for eight weeks.
Study NCT00758563 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluoride
Description: Brush twice daily
Study NCT01329328 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vibrating platform (Bioplate RF)
Description: whole body vibration exercise with multiple positions, with or without localized delivery of heating radiofrequency
Study NCT00996372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flibanserin
Description: patients will be randomized to flibanserin or placebo in a double-blind manner
Study NCT00996372 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: patients will be randomized to flibanserin or placebo in a double-blind manner
Study NCT02313844 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Viralym-B
Description: Follow-up Assessments: The timing of follow-up visits is based on the date of Viralym-B infusion. If a patient has multiple Viralym-B infusions the schedule resets again at the beginning so follow up relates to the last Viralym-B infusion.~Follow up will occur at 7 days, 14 days, 21 days, 28 days, 42 days, 90 days, 180 days, and 365 days post enrollment.
Study NCT02280655 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Storage-aged red blood cells (saRBCs) units
Description: Packed RBCs units stored for greater than 21 days, with a mean storage duration of 29.6 ± 4.9 days (mean ± SD)
Study NCT02280655 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fresh red blood cells units
Description: Packed RBCs units stored for less than 14 days, with a mean storage duration of 9.6 ± 3.9 days (mean ± SD)
Study NCT00698802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EX1000
Description: Treat-to-target titration scheme, s.c. injection
Study NCT00698802 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic human insulin
Description: Treat-to-target titration scheme, s.c. injection
Study NCT02422121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RNS60
Study NCT02422121 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03149406 — intervention group
Intervention type: OTHER
Intervention: Comparing the expression of miRNAs
Description: by PCR, in symptomatic and asymptomatic carotid plaques.
Study NCT02867046 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S1 transforaminal epidural steroid(dexamethasone) injection
Description: medial approach group (n=85): check intravascular injection while performing S1 transforaminal epidural steroid(dexamethasone) injection in medial side of S1 foramen under fluoroscopy~lateral approach group (n=85): same as medial approach group except using lateral side of S1 foramen
Study NCT02867046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1 transforaminal epidural steroid(dexamethasone) injection
Description: medial approach group (n=85): check intravascular injection while performing S1 transforaminal epidural steroid(dexamethasone) injection in medial side of S1 foramen under fluoroscopy~lateral approach group (n=85): same as medial approach group except using lateral side of S1 foramen
Study NCT01254981 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Description: Implantation of coronary stent
Study NCT03492463 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-nicotine e-cigarettes
Description: Participants will use e-cigarettes not containing nicotine while switching from cigarette use to use of e-cigarettes for eight weeks.
Study NCT01048190 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Poliomyelitis Vaccine (Sabin strains)
Description: 15 infants received 3 doses of formulation C vaccine and 15infants received 3 doses of placebo 3x0.5ml intramuscular injections, one month apart.
Study NCT01048190 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Poliomyelitis Vaccine (Sabin strains)
Description: 15 infants received 3 doses of formulation B vaccine and 15infants received 3 doses of placebo 3x0.5ml intramuscular injections, one month apart;
Study NCT01048190 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Poliomyelitis Vaccine (Sabin strains)
Description: 15 infants received 3 doses of formulation A vaccine and 15infants received 3 doses of placebo 3x0.5ml intramuscular injections, one month apart.
Study NCT05437224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan
Description: eligible subjects received 5 mg ambrisentan orally once daily for a 12-week primary evaluation period. Subjects then proceeded to a 12-week dose adjustment period during which dose titration to 10 mg was allowed.
Study NCT02426658 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02426658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed Disodium
Description: Given IV
Study NCT02426658 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: QOL studies
Study NCT04516018 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold exposure
Description: Subjects will be exposed to shivering thermogenesis for at least 1 hour for 10 days
Study NCT05809882 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magstim RAPID2 neuromagnetic stimulator (Magstim) with an 8-type coil
Description: frequency range, 20 Hz; 90% motion threshold; 3 s of stimulation; a 57 s interval; 15 min of stimulation for each side, five times per week for a total of 20 times
Study NCT05809882 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magstim RAPID2 neuromagnetic stimulator (Magstim) with an 8-type coil
Description: frequency range, 20 Hz，60% motion threshold; 3 s of stimulation; a 57 s interval; 15 min of stimulation for each side, five times per week for a total of 20 times. But with no stimulating energy output.
Study NCT00395681 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diprivan
Description: Propofol 200 mg versus 350 mg
Study NCT00567307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Red Heart Pill 2b (Polypill)
Description: Arm A will receive the polypill (Red Heart pill 2b) which is a combination of aspirin (75 mg), simvastatin (20g), lisinopril (10mg) and hydrochlorothiazide (12.5 mg)
Study NCT00567307 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Practice
Description: Arm B will receive management of their CVD risk according to the usual care given to participants in similar conditions
Study NCT02520570 — intervention group
Intervention type: DRUG
Intervention: ulinastatin
Description: We wouldn't intervene the doctors how to treat with the patients or how to use the drug, we just observe the react of patients after treated with ulinastatin.
Study NCT02155829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Study NCT02155829 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Riluzole)
Study NCT02834689 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking
Description: Walking on a treadmill at 3.5 METS for 50 minutes
Study NCT02834689 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Seated Control
Description: Sitting for 50 minutes
Study NCT04564313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab treatment
Description: Camrelizumab (SHR-1210), 200mg, I.V., Q3W
Study NCT01085279 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fraxel Restore, Solta Medical Inc. (Non-ablative fractional laser)
Description: 1,550 nm non-ablative fractional laser Irradiance: 15 mJ/microbeam. Coverage: 14-20%. Number of treatment sessions: 4-5
Study NCT04417751 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation
Description: The intervention includes 50 sessions, over the course of one year, being that 3 of those sessions will be the pretest, intratest and posttest evaluations. The intervention sessions will last approximately 45 minutes and they will be developed according to the following structure: welcoming and greeting the participants (5 minutes); reality orientation therapy (10 minutes), cognitive stimulation \[CS\] activity (25 minutes); return to calm and closure of the session, and session evaluation (5 minutes). CS sessions will be conducted in an individual intervention format. The intervention sessions will include several activities based on different non-pharmacological therapies (e.g., reminiscence therapy, reality orientation therapy, cognitive training) whose effectiveness in older adults with neurocognitive disorders has been scientifically proven. All individual CS sessions will be conducted by one therapist (clinical psychologist) with more than five years of experience in CS.
Study NCT01085279 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modified Kligman's formula (Triple topical therapy)
Description: Hydroquinone 5%, tretinoin 0.05%, triamcinolone acetonide 0.1% once a day during 15 weeks
Study NCT02057354 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: The goal of the aerobic exercise training is to increase aerobic endurance. Walking on treadmill at moderate intensity with grade adjusted. Exercise tailored to individual ability level.
Study NCT02057354 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise
Description: The goal of the aerobic exercise training is to increase aerobic endurance. Walking on treadmill at moderate intensity with grade adjusted. Exercise tailored to individual ability level.
Study NCT02057354 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-Aerobic Exercise
Description: The goal of this training is to improve overall muscle strength, balance and flexibility. Participants will do strength, balance and stretching exercises. Exercises tailored to individual ability level.
Study NCT02057354 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-Aerobic Exercise
Description: The goal of this training is to improve overall muscle strength, balance and flexibility. Participants will do strength, balance and stretching exercises. Exercises tailored to individual ability level.
Study NCT04007302 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: measurement of bilateral activity of the prefrontal cortex by a NIRS system (near infrared spectroscopy)
Description: measurement of the cerebral oxygenation response by the use of the Near Infrared Spectroscopy (NIRS) method
Study NCT04007302 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: measurement of bilateral activity of the prefrontal cortex by a NIRS system (near infrared spectroscopy)
Description: measurement of the cerebral oxygenation response by the use of the Near Infrared Spectroscopy (NIRS) method